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Use of metabolomics for the identification
and validation of clinical biomarkers for
preterm birth: Preterm SAMBA
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Rodolfo C. Pacagnella1, Silas G. Villas-Boas5, Jussara Mayrink1, Renato Passini Jr1, Kleber G. Franchini6,
Philip N. Baker2 and for the Preterm SAMBA and SCOPE study groups
Abstract
Background: Spontaneous preterm birth is a complex syndrome with multiple pathways interactions determining
its occurrence, including genetic, immunological, physiologic, biochemical and environmental factors. Despite great
worldwide efforts in preterm birth prevention, there are no recent effective therapeutic strategies able to decrease
spontaneous preterm birth rates or their consequent neonatal morbidity/mortality. The Preterm SAMBA study will
associate metabolomics technologies to identify clinical and metabolite predictors for preterm birth. These innovative
and unbiased techniques might be a strategic key to advance spontaneous preterm birth prediction.
Methods/design: Preterm SAMBA study consists of a discovery phase to identify biophysical and untargeted
metabolomics from blood and hair samples associated with preterm birth, plus a validation phase to evaluate
the performance of the predictive modelling. The first phase, a case–control study, will randomly select 100
women who had a spontaneous preterm birth (before 37 weeks) and 100 women who had term birth in the
Cork Ireland and Auckland New Zealand cohorts within the SCOPE study, an international consortium aimed
to identify potential metabolomic predictors using biophysical data and blood samples collected at 20 weeks
of gestation. The validation phase will recruit 1150 Brazilian pregnant women from five participant centres and will
collect blood and hair samples at 20 weeks of gestation to evaluate the performance of the algorithm model
(sensitivity, specificity, predictive values and likelihood ratios) in predicting spontaneous preterm birth (before
34 weeks, with a secondary analysis of delivery before 37 weeks).
Discussion: The Preterm SAMBA study intends to step forward on preterm birth prediction using metabolomics
techniques, and accurate protocols for sample collection among multi-ethnic populations. The use of metabolomics
in medical science research is innovative and promises to provide solutions for disorders with multiple complex
underlying determinants such as spontaneous preterm birth.
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Background
Despite improvements in antenatal and neonatal care,
the number of premature newborns each year has
not significantly decreased since the 1960s. Preterm
birth (PTB) is the leading cause of neonatal morbid-
ity and mortality and a major contributor to loss of
life, long-term disability, and health care costs [1–4].
The associated morbidity, mortality and high health
costs have been well documented with premature
infants facing life-threatening short and long term
complications [5–8].
Despite the enormity of the health economic burden
of preterm birth, and many years of focused research, a
common aetiology and/or predictive test have not yet
been identified. Spontaneous preterm birth (sPTB) is
considered one of the “Great Obstetrical Syndromes”,
which are conditions resulting from complex interac-
tions between the maternal and fetal genome and the
environment and which have a long preclinical period,
fetal involvement and adaptive functioning in nature [9].
This reflects the multifactorial nature of this condition
and the need to apply strategies that are capable of iden-
tifying multiple markers simultaneously in parallel with
the assessment of clinical and biophysical risk factors.
There are many clinical [10–13] and biochemical risk
factors [14–16] associated with sPTB and it is likely that
these biochemical markers are present in the maternal
blood long before the onset of a preterm labour. How-
ever, although certain candidate-driven approaches to
studying these changes show promise, this has not re-
sulted in effective predictive biomarkers for the general
pregnant population. Due to these complex and dynamic
characteristics of sPTB syndrome, it remains a difficult
task to identify women and babies at risk.
Currently, the selection of women likely to deliver
prematurely from clinical risk factors alone lacks the
sensitivity required to effectively identify the majority
of patients at risk of idiopathic sPTB [14]. Furthermore,
parameters derived from previous obstetric history can-
not be applied to nulliparous women. The association
of biophysical predictors such as cervical length and/or
vaginal biomarkers (fibronectin and phosphorylated
insulin-like growth factor binding protein-1) enhances
accuracy for prediction and enables more effective in-
terventions for selected women. There are therapeutic
interventions available for the prevention of sPTB, such
as the use of progesterone [10, 17, 18] and cervical pes-
sary [19]. Despite advances in selection of eligible
women for such therapeutic interventions, the efficacy
of cervical length or fetal fibronectin levels in asymp-
tomatic women are still limited and seem to be more
capable of discriminating women at lower risk than
those at higher risk [20–22]. Owen et al. showed that
almost 50 % of women with cervical length between 15
and 25 mm did not deliver before 35 weeks, as well
as approximately 70 % with cervical length between
25–30 mm [23].
The development of a predictive test for spontaneous
preterm birth would help to accurately identify a high-
risk population. To be effective, therapies need to be
commenced at a gestational age in which they are likely
to be of benefit. A sensitive early pregnancy-screening
test would facilitate the timely administration of prophy-
lactic treatments to those women at highest risk. The
development of physics, biology and medicine transla-
tional research can provide a comprehensive approach
for biological processes with complex pathways and reg-
ulations. Metabolomics offers an unbiased hypothesis
generating approach to identify and validate potential
candidate metabolomic biomarkers [24, 25].
We propose a multi-strategy approach to biomarker
discovery and validation through the establishment of a
large early pregnancy biobank of appropriate samples, in
conjunction with the application of analytical methods
capable of quantifying multiple blood-borne species sim-
ultaneously, and using some clinical and epidemiological
markers to identify women at highest risk of spontan-
eous preterm birth.
The development of predictive tests that translate
into clinical care can be divided into two distinct
phases; (i) hypothesis generation after acquisition of
data, a non-biased process where no or limited bio-
logical knowledge is required and (ii) validation of gen-
erated hypotheses [26]. The Preterm SAMBA study
goal spans both phases and aims to identify a clinically
useful early pregnancy-screening test to ascertain which
pregnancies are at risk of developing sPTB. Discovery-
based methods will be applied to blood and hair sam-
ples taken from carefully matched phenotypes in both
cohorts (preterm and term deliveries) to develop a pre-
dictive algorithm to identify those women at increased
risk of sPTB and test the effectiveness of such an algo-
rithm in a prospective cohort.
Methods/design
Preterm SAMBA, an international collaborative multi-
centre study for the development of predictive tests
that translate into clinical care, can be divided into two
distinct phases: The first component (Discovery phase)
is a case–control study that aims to identify clinical
and metabolomics biomarkers related to spontaneous
preterm birth. For this initial phase, untargeted meta-
bolomics techniques will be employed to identify and
quantify potential predictor’s metabolites that can be
associated to potential clinical predictors. The second
component (Validation phase) is a cohort study devel-
oped to validate the algorithm of prediction using the
clinical and metabolomics biomarkers discovered in
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the first component of the study. Thus, to evaluate the
performance of the prediction model developed at the
first phase, targeted metabolomics techniques will be
employed to analyse participants’ blood and hair sam-
ples to quantify those specific metabolites identified as
potential predictors of preterm birth.
Discovery phase
The initial phase of the project consists of a case–con-
trol study utilizing data and samples collected for the
SCOPE study (Screening for Pregnancy Endpoints
study). The SCOPE consortium was an international
effort to determine the causes and potential predictors
for pregnancy complications and its methodology had
already been previously published [27–29]. Briefly, the
cohort comprised 5690 healthy pregnant women re-
cruited between November 2004 and August 2008 in
New Zealand, Australia, Ireland and United Kingdom.
Inclusion and exclusion criteria for the SCOPE study are
described in Tables 1 and 2, respectively. Exclusion cri-
teria include major fetal anomaly, chronic hypertension,
diabetes, renal disease, systemic lupus erythematous, and
antiphospholipid syndrome. These will therefore be the
same criteria for the current study.
Extensive sociodemographic and physical data will be
collected including age, ethnicity, socio-economic status,
dietary and lifestyle questionnaire, parity, BMI (body
mass index) and cigarette smoking.
Plasma and serum samples will be collected at
20 weeks of gestation using stringent standard operating
procedures designed for metabolomics studies, barcoded
and stored at −80 °C within 2–4 h; the timing between
collection and freezing will be known for all specimens.
Several Standard Operating Procedures (SOP) for sam-
ple preparation by removal of proteins via ultrafiltration
were developed and validated. The analysis of deprotei-
nized plasma samples will be performed employing gas
chromatography and liquid chromatography mass spec-
trometry (GC-MS and LC-MS). GC-MS and LC-MS
techniques will be performed as described previously
[30, 31]. Quality control samples (acquired by pooling
plasma from all subjects) will be interspersed in every
5th run to assess reproducibility and validity. It is envis-
aged that the socioeconomic/physical/biomarker discov-
ery phase of the Preterm SAMBA study will identify
several candidate markers and predictive multivariate
models. Discriminatory metabolites will be translated to
a targeted triple quad MS (QQQ-MS) platform, to be
used in the validation phase.
The proportion of pregnancies complicated by any
preterm birth is approximately 10 %. Preterm SAMBA
Discovery Phase will randomly select 100 women (n =
100) whose pregnancies reached term as compared to
fifty randomly sampled pregnancies (n = 50) complicated
by spontaneous preterm birth prior to 37 weeks gesta-
tion, in each of the Cork Ireland and Auckland New
Zealand SCOPE cohorts (Fig. 1). The 20th week samples
and data will be analysed to identify sPTB potential pre-
dictors. Considering there were no previous studies on
this topic for preterm birth, these numbers were empir-
ically estimated using a similar study performed for pre-
eclampsia [31]. Using a type I error of 0.01, type II error
of 0.10, a ratio between controls and cases of 1:1, an
AUC of 0.9 and an OR of 10, the estimated sample of
preterm birth is 49. We then anticipated around 50
preterm birth for each of the two centers.
Validation phase – the Brazilian multicentre cohort study
The Preterm SAMBA validation phase consists of a
Brazilian multicentre cohort study with 1150 low-risk
pregnant nulliparous women. Five of the 27 members of
the Brazilian Network for Studies on Reproductive and
Perinatal Health (BNSRPH), were chosen to participate
in the Brazilian cohort (Table 3). Previous excellence
performance in epidemiological and translational studies
and diversity of cultural, ethnical and sociodemographic
population characteristics were criteria for centre selec-
tion. Therefore, there are participating centres in three
of the five regions of Brazil, which are the three most
populated regions of the country: Northeast, Southeast
and South.
Table 1 Inclusion criteria of Preterm SAMBA validation phase –
Brazilian cohort
• Singleton pregnancy
• Nulliparous (no previous delivery ≥20 weeks)
• Up to 21 weeks of gestational age
Table 2 Exclusion criteria of Preterm SAMBA validation phase –
Brazilian cohort
• Unsure LMP and unwilling to have dating US • Major Uterine Anomaly
• ≥3 Miscarriages • Cervical Suture
• Major Foetal Anomaly/Abnormal Karyotype • Knife cone biopsy
• Essential Hypertension Treated Pre-pregnancy • Ruptured membranes
now
• Mod-Severe Hypertension at booking
(≥160/100 mmHg)
• Long term Steroids
• Pre-pregnancy Diabetes • Low-dose Aspirin
• Renal Disease • Calcium (>1 g/24 h)
• Systemic Lupus Erythematosus • Eicosapentaenoic acid
(fish oil)
• Anti-phospholipid Syndrome • Vit. C ≥1000 mg & Vit. E
≥400 UI
• Sickle Cell Disease • Heparin/LMW Heparin
• HIV or Hep B or Hep C positive
Cecatti et al. BMC Pregnancy and Childbirth  (2016) 16:212 Page 3 of 9
Assuming a type I error rate, α, of 5 % and an esti-
mated area under ROC curve of at least 0.68, then in
order to test hypotheses to a suitable level of power
(80 % power, β = 0.2), the sample size sufficient should
approximate to 80 cases of spontaneous preterm birth
(<34 weeks gestation), calculated using MEDCALC®.
Based on a minimum expected preterm birth rate of
7 %, the total cohort size should therefore be of approxi-
mately 1150 subjects, around 230 women at each par-
ticipating centres.
Recruitment and data collection
The recruitment strategies include approaching existing
pregnant women in participating facilities during pre-
natal care visits and with website/internet, flyers and
local community advertisings. After the identification of
potential participants, the research assistant will invite
women and obtain an informed consent form of those
who meet the inclusion criteria and agree to participate.
Maternal age and ethnicity will be recorded from all
approached women to facilitate a comparison of those
who are recruited and those who decline.
All collected data will preferably be entered directly
into the database, but printed forms will also be available
in case of inability to access the internet-based database.
In such cases, the data will be then entered later and
completed printed forms will be stored, according to the
required ethical principles.
Sociodemographic, physical data and pregnancy outcomes
First Visit (19–21 weeks): similarly to the SCOPE study,
detailed information of sociodemographic characteristics
(age, socioeconomic status, education, ethnicity, occupa-
tion and type of maternity care), maternal medical and
obstetric history, infertility history, drugs and medications
use, family medical and obstetric history and current
pregnancy (occurrence and details of infection, vaginal
bleeding, dipstick proteinuria, intercourse and hospital
admission) will be collected.
Anthropometric measurements of maternal body
mass index, height, weight, head circumference, arm
circumference and triceps, biceps subscapular and
suprailiac skinfolds will be performed according to
standardized techniques. Height and weight of lightly
clothed women will be measured to the nearest 0.1 mm
and 0.1 kg respectively. Head and arm circumferences
will be measured with an inelastic tape and skinfold
thicknesses will be measured on the same side of the
body to the nearest 0.2 mm using Harpenden (and/or
Lange) skinfold calliper. The calliper is placed 1 cm
distal to the firmly grasped skinfold, using the thumb
and the index finger, at 90° to the skin. A single meas-
urement is taken after 2 s.
Dietary intake will be assessed using a 24-h dietary
recall administered by a trained professional who will
query participants about food and beverage consumption
Fig. 1 Flowchart of Preterm SAMBA Discovery Phase participants (Case-control component)
Table 3 Participating centres in the Preterm-SAMBA study
validation phase – Brazilian cohort
Maternity of CAISM, University of Campinas, in Campinas, São Paulo.
Maternity of the School of Medicine from UNESP, in Botucatu, São Paulo.
Maternity of the Clinic Hospital, Federal University of Rio Grande do
Sul, in Porto Alegre, Rio Grande do Sul.
Maternity of the Clinic Hospital, Federal University of Pernambuco, in
Recife, Pernambuco.
MEAC – School Maternity of the Federal University of Ceará, in
Fortaleza, Ceará.
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in the previous 24 h. A trained nutritionist will then esti-
mate calories, macro and micronutrient intake using
computer-based standard tables allowing for appropriate
ethnic, social and regional variations.
Furthermore, three consecutive manual blood pressure
measurements will be recorded, using an appropriate
cuff size for different arm circumferences and using
Korotkoff phase V for diastolic blood pressure.
Second and third Visit (27–29 weeks and 37–39
weeks; both optional): three consecutive manual blood
pressure measurements, anthropometric parameters
(weight, height, head and arm circumference and tri-
ceps, biceps, subscapular and suprailiac skinfolds) and
occurrence and characteristics of infection, vaginal
bleeding, dipstick proteinuria, intercourse and hospital
admissions will be recorded.
Postpartum data: data will be collected from the
participant’s medical record, the prenatal chart and/or
from a personal interview with the participant during
hospital admission to minimize missing information.
The main outcome is spontaneous preterm birth, de-
fined as a birth before 34 weeks of gestational age due to
preterm labour or premature rupture of membranes.
Secondary outcomes will also be evaluated: spontaneous
preterm birth alternatively defined as a birth before
37 weeks of gestational age due to preterm labour or
premature rupture of membranes, provider-initiated
preterm birth, defined as preterm birth due to medical
indication on account of maternal or fetal conditions;
pre-eclampsia, defined as having systolic blood pres-
sure ≥ 140 or systolic blood pressure ≥ 90 mmHg after
20 weeks gestation on at least two occasions apart of
20 min, and/or proteinuria (24-h urinary protein ≥
300 mg or urine dipstick ≥ ++) and/or severe maternal
complications [32]; gestational diabetes mellitus ac-
cording to ADA guidelines [33]; fetal growth restric-
tion (FGR) defined as having birthweight below 10th
percentile based on GROW customised birthweight
centiles [34]. Clinical data will also be collected regarding
the occurrence of preterm labour, cervical cerclage, deep
vein thrombosis, infection, vaginal bleeding, dipstick
proteinuria, intercourse, hospital admission, deep vein
thrombosis during pregnancy and puerperium, and mater-
nal mortality and the use of progesterone and/or pessary,
tocolytic, antibiotic for preterm labour or pPROM, corti-
costeroids for fetal maturation, magnesium sulphate for
neuroprotection during pregnancy. The occurrence of
severe maternal morbidity and near miss will also be
reported according to WHO guidelines [35]. Neonatal
outcomes related to neonatal morbidity and mortality will
be recorded until newborn discharge or death.
Sample collection, processing and storage
Non-fasting blood samples will be collected at 20 (be-
tween 19 and 21) weeks of gestational age (Fig. 2). All
research assistants will be trained according to specific
and detailed Standard Operation Protocols (SOPs) devel-
oped for sample collection, processing and storage. One
of the study coordinators was trained by the SCOPE
team, to guarantee adequate understanding of all neces-
sary procedures. A maximum of 20 mL of blood will be
collected to provide serum and plasma specimens. The
blood specimens will be stored in 250 μL 2-D barcoded
cryovials after one centrifugation cycle for plasma speci-
mens (2000×g for 10 min at 4 °C) and two centrifugation
cycles for serum (2000×g for 10 min and 2400×g for
10 min at 4 °C). The blood samples will be processed
and frozen at −80 °C within 2–4 h. The time interval
between collection and freezing will be recorded for
all specimens.
Although the Preterm SAMBA strategy and work-
flow is focussed around the analysis of blood samples,
we recently reported a proof-of-concept study, which
highlighted the potential use of the hair metabolome
in the prediction of pregnancy complications [36].
Hair samples will also be collected at 20 weeks’ gestation.
Samples (20–30 hair strands for each participant) will be
collected from the occipital area, 0.5 cm away from the
scalp, using blunt scissors. Then, hair will be packed in
aluminium foil and stored at room temperature [36]. A
unique linear barcode will be pasted on each hair package.
All specimens and quality control information will be
registered in the database.
Database
A specific database for the Preterm SAMBA Brazilian
Cohort was developed together with MedSciNet, a
Swedish based company specialized in the design and
Fig. 2 Visits of Preterm-SAMBA Validation Phase
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development of online database systems linked with bio-
banks management systems, similarly to the database
previously used for the SCOPE. The preterm SAMBA
database will be centralized, secure, internet-based and
FDA (United States Food and Drug Administration) and
HIPAA (Health Insurance and Accountability Act of
1996, United States Security and Privacy Rules) compli-
ant, which allows continuous data entry and monitoring
of study progress. Completeness of clinical data and
specimen collection will be constantly monitored, with
incomplete fields ‘flagged’ for attention. The database
allows several monitoring procedures with hierarchical ac-
cess licenses and tracking system for all specimen aliquots
stored. To comply with biobank regulatory issues, patients
will only be identified by a unique study number. Pseudo-
anonymised metadata and interim data will be stored
using our laboratory information management system.
The identifying information about participants will be
kept in a separate and secure local database.
Data and sample quality
Several procedures to enhance and assure data and
sample quality will be adopted. All entered data will
be prospectively and retrospectively monitored. Dur-
ing data entry, internal consistency of variables is per-
formed and error messages are automatically flagged.
After completing the collection of data from a partici-
pant, all information needs to be reviewed by a local
monitor. Then, the final form has to be signed by the
local principal investigator (PI) in order to be incor-
porated in the final database. The coordinating centre
(Campinas, Brazil) will also perform a centralized
monitoring of data and samples. An initial meeting
with all researchers from Brazilian participating centres
has been held to discuss the final protocol, procedures to
be implemented, their particular characteristics and
necessary approaches to be used to guarantee the im-
plementation of the study. Another general meeting
at the end of study is planned in order to discuss re-
sults, strategies for manuscripts’ writing and submis-
sion and other related topics.
The coordinating centre will randomly select approxi-
mately 10 % of printed completed forms to carry out a
check and validation of data from the forms and data-
base entry during the first and second half of the study.
This double-check procedure enhances data quality and
decreases typing errors.
The record of information regarding sample collection,
processing (precentrifugation and centrifugation) and
storage processes will follow the Standard Preanalytical
Coding for biospecimens (SPRECs) protocol, developed
and recommended by the International Society for
Biological and Environmental Repositories Biospecimen
(ISBER) Science Working Group [37]. This protocol
enables standardization of preanalytical information,
using standard codes to refer to the techniques and con-
ditions to which the samples were submitted.
Metabolomics analysis
The precise methodology to be used in the validation
phase will depend on the ongoing discovery studies. As
detailed above we anticipate that it will be based on a
targeted triple quad MS (QQQ-MS) platform, as previ-
ously described [38]. We will subsequently describe de-
tails relating to metabolomics analysis techniques and
metabolomics statistical analyses. We anticipate that
data analysis will be integrated into the relational data-
base such that decision rules may combine both clinical
and spectrometric data.
The performance of the final algorithm developed in
the discovery phase will be evaluated by its capacity to
predict spontaneous preterm birth occurrence in
women from the Brazilian cohort. The validation will
be performed using the average squared difference be-
tween predicted and observed outcome (R2), adjusted
R2 (same as R2, but penalizes for the number of predic-
tors), sensitivity, specificity, positive and negative pre-
dictive values, likelihood ratio and the area under the
ROC curve.
Ancillary studies
The Preterm SAMBA Brazilian cohort study will collect
additional data regarding other relevant maternal and
fetal obstetric complications. Detailed clinical data re-
lated to the occurrence and severity of pre-eclampsia,
fetal growth restriction and gestational diabetes mellitus
will be recorded. Fetal growth restriction will be diag-
nosed if birthweight is below 10th customised percentile.
The occurrence of severe maternal morbidity, maternal
near miss and maternal mortality during pregnancy or
up to discharge after delivery will also be recorded, ac-
cording to WHO definitions [35].
Ethical aspects
The SCOPE study, whose data and samples will be ana-
lysed for the Preterm SAMBA discovery phase, was ap-
proved by local ethics committees in New Zealand and
Ireland and registered in the Australian and New Zealand
Clinical Trial Registry (ACTRN12607000551493) [28]. All
women who participated in the SCOPE study provided
written informed consent and agreed to have their data
and samples used in other studies. The Preterm SAMBA
study has been reviewed and approved by the National
Committee for Ethics in Research of Brazil (CONEP)
and by the Institutional Review Board (IRB) of the co-
ordinating centre (Letter of approval 1.048.565 issued
on 28th April 2015) and of all other Brazilian participat-
ing centres. All women who will be enrolled in the
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Preterm SAMBA Brazilian cohort (Validation phase)
will sign an informed consent form, also allowing for
future additional studies with their biological samples
without any additional consent.
The ethical principles stated in the Brazilian National
Heath Council (Resolution CNS 466/12) will be
respected in every stage of this study. The anonymity of
the source of information will be guaranteed and the
care for the women will be provided independent of her
agreement to participate in the study. All ethical princi-
ples related to biobank storage and transport will be
followed according to national and international rules
related to research with human beings. The study also
complies with the Declaration of Helsinki amended in
Hong Kong in 1989. The methodological and ethical as-
pects of Preterm SAMBA study protocol were developed
following STROBE guidelines [39].
Discussion
The “Omics” Science comprises genomics, transcripto-
mics, proteomics and metabolomics technologies,
which each provide valuable translational surveys in
biological processes. A metabolomics approach en-
ables the evaluation of metabolic pathways and the
correlation of biochemical changes related to patho-
physiology of disease, providing a downstream result
of gene expression and higher sensitivity to phenotype
of disease [40–45]. Underlying conditions and factors
related to the occurrence, severity or prognosis of dis-
eases with complex determinants may be assessed,
bringing to light the final product of organism metab-
olism: the metabolome [42].
The development of a two-phase metabolomics re-
search program that includes two large cohorts of
nulliparous women is not an easy task. The network col-
laboration is essential to develop, implement and analyse
such complex data and, more importantly, to achieve
reliable results. Precise protocols for sample collection,
processing, storage and biobank management will be
essential to assure high quality data and results.
Metabolomics profiling requires different techniques
to address the detection and quantification of different
classes of metabolites once there is no current method
capable to identify all of them. Preterm SAMBA study
will employ different untargeted techniques that require
very carefully and standardized protocols for sample
preparation [24]. Studying the metabolome in blood
samples requires invasive collection and immediate pro-
cessing. As an alternative, hair samples are non-invasive,
do not need processing methods and can be stored at
room temperature. Hair can, theoretically, reflect en-
dogenous compounds and environmental exposures
from many days/weeks ago. The determination of the
hair metabolome is a possible approach to identify
biomarkers for spontaneous preterm birth. It has already
been explored in gestational diabetes and fetal growth
restriction, revealing potential endogenous mechanisms
involved in those pathologic conditions [36, 45].
The identification of spontaneous preterm birth pre-
dictors using multi-ethnic data/samples and the evalu-
ation of performance in a culturally and ethnically
different population is desirable and meaningful for
external validation. The use of quality control records
and SPREC protocol is another important recommenda-
tion for metabolomics studies due to the necessity to
evaluate confounders for analytical measures such as the
time between sample collection, storage and processing
conditions and the occurrence of haemolysis, lipaemia
and metabolic degradation on account of inadequate
temperature or solar exposure [37].
In the context of translational research, metabolo-
mics may enhance understanding of the underlying
pathways, which lead to obstetric complications. Pre-
term SAMBA aims to identify and validate a predict-
ive model for spontaneous preterm birth, but will also
develop a biobank and database that will enable re-
search on pre-eclampsia (PE), fetal growth restriction
(FGR) and gestational diabetes mellitus (GDM). The
possibility to combine biochemical, genetics and clin-
ical information that can be large-scale and replicable
empowers the development of knowledge for clinical
practice in preterm birth prevention. This would be
especially worthwhile and helpful for countries with a
high proportion and high absolute number of preterm
births as is the case of Brazil where around 12 % of
all births occur prematurely [46].
A recent clustered designed study showed that 30 %
of all spontaneous preterm births do not have any ma-
ternal, fetal or placental conditions identified that could
be related to its occurrence [47]. The application of
metabolomics techniques could be a promising ap-
proach for spontaneous preterm birth prediction, all
the more in those cases of silent phenotype in which
there are no known predictors. Metabolomics have
been already described in other obstetric conditions as
pre-eclampsia, gestational diabetes mellitus and fetal
growth restriction [31, 40, 41, 45, 48, 49], showing
excellent performance in terms of a discriminatory
algorithm. Therefore, we believe metabolomics is a
powerful and strategic key not only for preterm birth
prediction, but hopefully also for its prevention. The
detection of metabolic pathways related to PTB syn-
drome may enable the development of more accurate
therapies for primary or secondary prevention of preg-
nant women identified as at high-risk.
At the end of the study, if we are successful in the
identification of such an effective algorithm, certainly
several other topics should be carefully considered.
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Can this knowledge be really translated into a com-
mercially available kit for screening purposes? Would
the costs derived from this process be acceptable for
low and middle-income countries? How will this be
made available for populations in public sector? For dis-
cussing a future implementation of such a screening strat-
egy, the following necessary points to be covered are to
know if a concrete package of interventions to reduce
preterm birth among those women identified as high-
risk is available, and if it is cost-effective to be sup-
ported by the public health system. Finally, in this study
we are planning to transfer the technology developed
for the algorithm from New Zealand to Brazil, includ-
ing lab technologies for assessing the biomarkers iden-
tified by metabolomics for preterm birth. Hopefully, if
this is proved to be feasible, we believe that an import-
ant step for reducing the burden of preterm birth will
have been achieved.
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